Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to ...
Hosted on MSN11h
Amgen Earnings Transcript (NASDAQ:AMGN)Presentation Unidentified Speaker Thank you. Thank you, Julianne. Good afternoon, everyone, and welcome to our 4th-quarter ...
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback